“Anti-Diabetic Drugs and those for cardiovascular diseases are
expected to see the fastest growth in 2011. Cardiovascular patients will
increase to 251 million in 2010, with the greatest rate of growth
forecast for the US market. This is due to the changes in demographics
and lifestyle that will boost the cardiovascular sales. However, the
growth rates will be limited by continued patent expiries for major
products and due to the lack
of novel therapies. The anti-hypertensive
drugs
will dominate the global cardiovascular market
with a market share
of nearly 50%.”
|
|